ECSP22074680A - Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos - Google Patents

Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos

Info

Publication number
ECSP22074680A
ECSP22074680A ECSENADI202274680A ECDI202274680A ECSP22074680A EC SP22074680 A ECSP22074680 A EC SP22074680A EC SENADI202274680 A ECSENADI202274680 A EC SENADI202274680A EC DI202274680 A ECDI202274680 A EC DI202274680A EC SP22074680 A ECSP22074680 A EC SP22074680A
Authority
EC
Ecuador
Prior art keywords
receptor agonist
agonist peptide
gip receptor
dosing
peptide compounds
Prior art date
Application number
ECSENADI202274680A
Other languages
English (en)
Inventor
Nicholas Scorah
Antoine Henninot
Derek Cole
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP22074680A publication Critical patent/ECSP22074680A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona compuestos peptídicos agonistas del receptor de GIP adecuados para dosificación una vez al día (QD), en los que dichos compuestos peptídicos tienen una acción activadora sobre los receptores de GIP, y el uso del péptido agonista del receptor de GIP como medicamento para el tratamiento y/o la prevención de la emesis o un síntoma o una afección asociados con la emesis. Específicamente, se proporciona un péptido agonista del receptor de GIP que contiene una secuencia representada por cualquiera de las fórmulas (I)-(V) o una sal de este y un medicamento que lo comprende.
ECSENADI202274680A 2020-03-25 2022-09-23 Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos ECSP22074680A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062994716P 2020-03-25 2020-03-25

Publications (1)

Publication Number Publication Date
ECSP22074680A true ECSP22074680A (es) 2022-10-31

Family

ID=76502784

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202274680A ECSP22074680A (es) 2020-03-25 2022-09-23 Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos

Country Status (17)

Country Link
US (1) US20220227830A1 (es)
EP (1) EP4126921A2 (es)
JP (1) JP2023519446A (es)
KR (1) KR20230005184A (es)
CN (1) CN115335395A (es)
AR (1) AR121650A1 (es)
AU (1) AU2021241257A1 (es)
BR (1) BR112022019114A2 (es)
CA (1) CA3173129A1 (es)
CL (1) CL2022002598A1 (es)
CO (1) CO2022014959A2 (es)
EC (1) ECSP22074680A (es)
IL (1) IL296592A (es)
MX (1) MX2022011816A (es)
PE (1) PE20230107A1 (es)
TW (1) TW202202516A (es)
WO (1) WO2021193984A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
NZ540381A (en) 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
WO2004041266A1 (ja) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
CA2550012A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
BRPI0418148A (pt) 2003-12-25 2007-04-17 Takeda Pharmaceutical composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
CA2617969A1 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
ME00535B (me) 2006-06-27 2011-10-10 Takeda Pharmaceuticals Co Fuzionisana ciklična jedinjenja
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
NZ576570A (en) 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
PE20151770A1 (es) * 2013-05-28 2015-12-11 Takeda Pharmaceutical Compuesto peptidico
JOP20180028A1 (ar) * 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2020067575A1 (en) * 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof

Also Published As

Publication number Publication date
AR121650A1 (es) 2022-06-22
TW202202516A (zh) 2022-01-16
JP2023519446A (ja) 2023-05-10
WO2021193984A3 (en) 2021-12-16
PE20230107A1 (es) 2023-01-25
CA3173129A1 (en) 2021-09-30
US20220227830A1 (en) 2022-07-21
CL2022002598A1 (es) 2023-06-02
CN115335395A (zh) 2022-11-11
AU2021241257A1 (en) 2022-10-13
KR20230005184A (ko) 2023-01-09
EP4126921A2 (en) 2023-02-08
BR112022019114A2 (pt) 2023-02-14
WO2021193984A2 (en) 2021-09-30
CO2022014959A2 (es) 2022-11-08
IL296592A (en) 2022-11-01
MX2022011816A (es) 2022-10-10

Similar Documents

Publication Publication Date Title
CO2019012271A2 (es) Péptido activador de receptor de gip
CL2019000663A1 (es) Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
ECSP15044389A (es) Compuesto peptídico
CL2021002772A1 (es) Moduladores de la vía de respuesta integrada al estrés
ECSP22074680A (es) Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
CL2020001817A1 (es) Moduladores del receptor c5a
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
CL2022002597A1 (es) Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
CO2022001814A2 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CL2021000329A1 (es) Compuestos útiles en terapia del vih
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
CO2020002967A2 (es) Desinfectante novedoso para criaderos
AR102248A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
CO2023011625A2 (es) Uso de luvadaxistat para el tratamiento de deterioro cognitivo
AR107750A1 (es) Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
AR110324A1 (es) Combinación herbicida con una difluorometansulfonilanilida sustituida con dimetoxitriazinilo